日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO

长期输注抗GD(2)抗体ch14.18/CHO治疗高危神经母细胞瘤患者的耐受性、反应和预后

Mueller, Ina; Ehlert, Karoline; Endres, Stefanie; Pill, Lena; Siebert, Nikolai; Kietz, Silke; Brock, Penelope; Garaventa, Alberto; Valteau-Couanet, Dominique; Janzek, Evelyne; Hosten, Norbert; Zinke, Andreas; Barthlen, Winfried; Varol, Emine; Loibner, Hans; Ladenstein, Ruth; Lode, Holger N

Crucial factors for the acceptance of a computerized national medication list: insights into findings from the evaluation of the Austrian e-Medikation pilot

计算机化国家药品目录被接受的关键因素:奥地利电子药品试点项目评估结果的启示

Hackl, W O; Hoerbst, A; Duftschmid, G; Gall, W; Janzek-Hawlat, S; Jung, M; Woertz, K; Dorda, W; Ammenwerth, E

Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System

人源和鼠源ACE2的重组表达和表征:替代性肾素-血管紧张素系统的物种特异性激活

Poglitsch, Marko; Domenig, Oliver; Schwager, Cornelia; Stranner, Stefan; Peball, Bernhard; Janzek, Evelyne; Wagner, Bettina; Jungwirth, Helmut; Loibner, Hans; Schuster, Manfred

Human recombinant ACE2 reduces the progression of diabetic nephropathy

人类重组 ACE2 减缓糖尿病肾病的进展

Gavin Y Oudit, George C Liu, Jiuchang Zhong, Ratnadeep Basu, Fung L Chow, Joyce Zhou, Hans Loibner, Evelyne Janzek, Manfred Schuster, Josef M Penninger, Andrew M Herzenberg, Zamaneh Kassiri, James W Scholey